Alizé Pharma 3 bags largest EU financing so far
Venture Captital specialist LSP led a 67m Series A financing in peptide developer Alizé Pharma 3.
Better TNF? receptor blockers on the horizon
Two research teams have unraveled the complex dynamics of TNF? receptor signaling and have identified compounds that may be safer than current treatments.
European Commission approves ten GMOs
The European Commission has authorised ten genetically modified products.
Zambon heading to US market with 500m acquisition
Zambon is set to acquire respiratory company Breath Therapeutics for up to 500m to complement its respiratory pipeline and get access to the US market.
Gut microbiome boosts muscle strength
Swedish researchers have demonstrated that the gut microbiome can significantly affect the proper development and strength of skeletal muscle.
Curetis lower respiratory tract panel ready for FDA clearance
Molecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections.
Merck and Broad Institute announce CRISPR license agreement
Merck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing.
Billions for the circular economy
Together with the EIB, five of the EUs largest national promotional banks and institutions plan to invest 10bn to accelerate the transition to a sustainable and circular economy.
Genmab launches US$502m IPO
Danish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline.
AM-Pharma raises 116m for Phase III
Dutch biopharma company AM-Pharma B.V. has secured 116m to bring its acute kidney injury treatment into Phase III.